Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001
NCT ID: NCT05697861
Last Updated: 2025-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
72 participants
OBSERVATIONAL
2023-07-10
2038-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation
NCT05638841
Prospective Evaluation of NfL as a Biomarker in ATTRv
NCT05879874
Study on Left Atrial Function of Atrial Fibrillation After Radiofrequency Ablation With Statin Therapy
NCT02776956
Combined Study of ATrial Strain and Voltage by High Density Mapping in Young Patients With Atrial Fibrillation.
NCT05565183
Left Atrial Appendage Occlusion Study III
NCT01561651
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. A subject has provided informed consent for the LTFU study.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Intellia Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Site
Paris, , France
Clinical Trial Site
Auckland, , New Zealand
Clinical Trial Site
Umeå, , Sweden
Clinical Trial Site
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-003405-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
ITL-2001-CL-999
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.